Clinical Efficacy of the Combination Therapy with Sitagliptin and Pioglitazone in Patients with Type 2 Diabetes
Objective To explore clinical efficacy of the combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes(T2 DM).Method A retrospective analysis was conducted on the case data of 77 patients with T2DM who were treated in the Third People's Hospital of Luoyang City from March 2021 to December 2023.The patients were divided into a control group(using pioglitazone alone,n=39)and a combination group(using semaglutide combined with pioglitazone,n=38),based on their different treatment methods.The clinical efficacy,incidence of adverse reactions,and various indices were compared between the 2 groups,including insulin function indicators[Homa-insulin resistance(HOMA-IR)and glucose infusion rate(GIR)],blood lipid levels[triglyceride(TG),high-density lipoprotein(HDL-C),total cholesterol(TC),and low-density lipoprotein(LDL-C)],and relevant serum factor levels[omentin-1(Omentin-1),interleukin(IL)-6,homocysteine(Hcy),and tumor necrosis factor(TNF)-α]before and after treatment.Results The total clinical effective rate in the combination group was significantly higher than that in the control group(P＜0.05):after treatment,the level of HOMA-IR in the combination group was lower than that in the control group,while the level of GIR was higher than that in the control group(both P＜0.05);the levels of TG,TC,and LDL-C in the combination group were lower than those in the control group,but the levels of HDL-C were higher than those in the control group(all P＜0.05);the level of Omentin-1 was higher in the combination group,whereas the levels of IL-6,Hcy,and TNF-α were lower compared to the control group(all P＜0.05);there was no statistically significant difference in the incidence of adverse reactions between the 2 groups(P＞0.05).Conclusion The study suggests that the combination therapy of semaglutide and pioglitazone for T2DM can be clinically effective through improving insulin function,regulating blood lipid levels,and inhibiting inflammatory responses in the body,with relatively desirable safety profile.
NETL
NSTL
万方数据
